Birkenstock Holding (NYSE:BIRK) Bolsa

Birkenstock Holding

Birkenstock Holding PLC is a company that manufactures and sells footbed-based products, including sandals, closed-toe silhouettes, and other products, such as skincare and accessories, for everyday, leisure, and work. It sells its products through two main channels: business-to-business (B2B) which comprises sales made to established third-party store networks, and direct-to-consumer (DTC) which comprises sales made on globally owned online stores through the Birkenstock.com domain and sales made in Birkenstock retail stores. The company's reportable segments are based on its regional hubs and include: the Americas which is also its key revenue-generating segment; Europe; and Australia, Japan, India, China, and the United Arab Emirates (APMA).

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

BIRK

Birkenstock revela sus ganancias del 4T, con proyecciones de ingresos y calificaciones de analistas clave. ¿Superará expectativas?

Acciones de Birkenstock (BIRK): Resultados financieros, proyecciones de crecimiento y la opinión de analistas clave

Birkenstock Holding PLC

Birks Group Inc

Guidance

Polaris Sees Q2 FY25 Sales Guidance Of $1.6B-$1.8B

WIIM

SANM

Sanmina shares are trading lower after the company reported Q2 financial results and issued Q3 guidance below estimates.

NXPI

NXP Semiconductors shares are trading lower after the company reported Q1 financial results and issued Q2 EPS guidance with its midpoint below estimates. The company announced CEO Kurt Sievers will retire at the end of 2025.

Verona Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.12) by 58.33 percent. This is a 40.63 percent increase over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $76.26 million which beat the analyst consensus estimate of $52.71 million by 44.67 percent.

Earnings

Earnings Beats

Earnings Misses

VRNA

Verona Pharma Q1 GAAP Earning per ADS $(0.19) Misses $(0.12) Estimate, Sales $76.26M Beat $52.71M Estimate

UCTT

Ultra Clean Holdings shares are trading lower after the company reported worse-than-expected Q1 financial result and issued Q2 guidance below estimates.

Enterprise Prods Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>) reported quarterly earnings of $0.64 per share which missed the analyst consensus estimate of $0.72 by 11.11 percent. This is a 3.03 percent decrease over earnings of $0.66 per share from the same period last year. The company reported quarterly sales of $15.42 billion which beat the analyst consensus estimate of $14.05 billion by 9.73 percent. This is a 4.45 percent increase over sales of $14.76 billion the same period last year.

Enterprise Prods Partners Q1 EPS $0.64 Misses $0.72 Estimate, Sales $15.42B Beat $14.05B Estimate

BYON

Beyond shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results.

TVGN

Tevogen Bio Holdings shares are trading higher after the company reaffirmed its oncology pipeline revenue forecast, projecting $1 billion in its launch year and a cumulative five-year estimate of $10 billion to $14 billion.

OKTA

Okta shares are trading higher after the company announced it will replace Berry Global Group in the S&P Midcap 400, effective before the opening of trading on Thursday, May 1.

General

MGRM

AI Robotic Company Monogram Obtains Regulatory Approval From India's Central Drugs Standard Control Organization To Import mBôs TKA System To Conduct Clinical Trials

Ares Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCC#NASDAQ">ARCC</a>) reported quarterly earnings of $0.50 per share which missed the analyst consensus estimate of $0.54 by 7.41 percent. This is a 15.25 percent decrease over earnings of $0.59 per share from the same period last year. The company reported quarterly sales of $732.00 million which missed the analyst consensus estimate of $777.10 million by 5.80 percent. This is a 4.42 percent increase over sales of $701.00 million the same period last year.

ARCC

Ares Capital Q1 Adj. EPS $0.50 Misses $0.54 Estimate, Sales $732.00M Miss $777.10M Estimate

ABEO

Abeona Therapeutics shares are trading higher after the company announced FDA approval of ZEVASKYN for treating wounds in patients with recessive dystrophic epidermolysis bullosa.

JOBY

Joby Aviation Completes Flights With A Full Transition From Vertical To Cruise Flight And Back Again With A Pilot Onboard

Polaris Is Withdrawing Full Year 2025 Guidance Due To Trade And Economic Uncertainty

Offerings

BSGM

BioSig Technologies Issued 2.75M Restricted Shares to Service Providers for Business Development Services

<ul>
<li>ZEVASKYN fills a critical need for people living with RDEB, a debilitating dermatological condition with no cure.</li>
<li>Approval based on the pivotal Phase 3 VIITAL study, showing ZEVASKYN resulted in significant wound healing and pain reduction after a single treatment with a favorable safety profile.</li>
<li>ZEVASKYN to be available through Qualified Treatment Centers beginning in 3Q 2025.</li>
<li>Abeona Assist patient services program offers personalized support for eligible patients and families throughout their treatment journey with ZEVASKYN.</li>
<li>Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA</li>
</ul>

Biotech

Health Care

The FDA Approves Abeona Therapeutics' Zevaskyn (Prademagene Zamikeracel) Gene-modified Cellular Sheets, Also Known As Pz-cel, As The First And Only Autologous Cell-based Gene Therapy For Wounds In Adult And Pediatric Patients With Recessive Dystrophic Epidermolysis Bullosa

SentinelOne Releases Purple AI 'Athena' With Agentic AI Capabilities To Mirror The Deep Security Reasoning

Polaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(0.91) by 1.1 percent. This is a 491.3 percent decrease over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $1.54 billion which met the analyst consensus estimate. This is a 11.53 percent decrease over sales of $1.74 billion the same period last year.

Polaris Q1 Adj. EPS $(0.90) Beats $(0.91) Estimate, Sales $1.54B Inline

Honeywell Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) narrows FY2025 GAAP EPS guidance from $9.39-$9.79 to $9.48-$9.78 vs $9.74 analyst estimate..

Honeywell Intl Narrows FY2025 GAAP EPS Guidance from $9.39-$9.79 to $9.48-$9.78 vs $9.74 Est

UPS Does Not Provide Full Year Outlook Update Citing Macro Economic Uncertainty

Press Releases

Birkenstock Announces Third Quarter 2024 (Ended June 30, 2024) Results Date and Conference Call

Birkenstock Reports Record Third Quarter Revenue, up 19% Year-Over-Year, Driven by Continued Strong and Growing Consumer Demand

Events

Birkenstock Announces September Conference Participation

Birkenstock Announces Fourth Quarter and Full Fiscal Year 2024 (Ended September 30, 2024) Results Date and Conference Call

Birkenstock Reports Fiscal 2024 Results: Revenue Growth and Adjusted EBITDA Ahead of Expectations

Birkenstock Announces First Quarter 2025 (Ended December 31, 2024) Results Date and Conference Call and January Conference Participation

Management

Ivica Krolo Appointed as New Chief Financial Officer of the Birkenstock Group

Birkenstock Reports Fiscal First Quarter 2025 Results: Revenues Up 19%

Birkenstock Announces Fiscal Second Quarter 2025 (Ended March 31, 2025) Results Date and Conference Call

Comments

Birkenstock Holding

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL